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CD4+T cells contribute to tumor eradication, even in the absence of CD8+T cells. Cytotoxic
CD4+ T cells can directly kill MHC class II positive tumor cells. More surprisingly, CD4+
T cells can indirectly eliminate tumor cells that lack MHC class II expression. Here, we
review the mechanisms of direct and indirect CD4+ T cell-mediated elimination of tumor
cells. An emphasis is put on T cell receptor (TCR) transgenic models, where anti-tumor
responses of naïve CD4+ T cells of defined specificity can be tracked. Some generaliza-
tions can tentatively be made. For both MHCIIPOS and MHCIINEG tumors, presentation of
tumor-specific antigen by host antigen-presenting cells (APCs) appears to be required for
CD4+ T cell priming. This has been extensively studied in a myeloma model (MOPC315),
where host APCs in tumor-draining lymph nodes are primed with secreted tumor antigen.
Upon antigen recognition, naïve CD4+ T cells differentiate into Th1 cells and migrate to
the tumor. At the tumor site, the mechanisms for elimination of MHCIIPOS and MHCIINEG
tumor cells differ. In a TCR-transgenic B16 melanoma model, MHCIIPOS melanoma cells
are directly killed by cytotoxic CD4+ T cells in a perforin/granzyme B-dependent manner.
By contrast, MHCIINEG myeloma cells are killed by IFN-γ stimulated M1-like macrophages.
In summary, while the priming phase of CD4+ T cells appears similar for MHCIIPOS and
MHCIINEG tumors, the killing mechanisms are different. Unresolved issues and directions
for future research are addressed.
Keywords: tumor immunology, CD4+ T cells, MHC class II, T cell receptor transgenic, transgenic mouse models,
tumor antigen,T helper 1, multiple myeloma
RECENT ADVANCES IN TUMOR IMMUNOLOGY
The field of tumor immunology has come a long way since the for-
mulation of the tumor immunosurveillance hypothesis by Thomas
and Burnet (1–4). Although still debated, increasing evidence
suggests that the immune system can detect and reject incipient
tumors, and that CD4+ and CD8+ T cells play an important role
as mediators of immunosurveillance (5). Furthermore, there is
accumulating evidence that the immune system is not completely
tolerant even to established tumors, based on the observation that
tumor-infiltrating T cells, when expanded in vitro and injected
back to lymphopenic patients, have a clinical effect in some
patients (6). Further supporting the notion of ongoing immune
responses to tumors, antibodies that block inhibitory molecules on
T cells induce long-term remission in a subset of cancer patients
Abbreviations: APC, antigen-presenting cell; CIITA, class II trans-activator;
FasL, Fas ligand; HA, hemagglutinin; Id, idiotype; IFN-γ, interferon gamma;
Ig, immunoglobulin; MHC, major histocompatibility complex; MM, multiple
myeloma; MOPC, mineral oil-induced plasmacytoma; OVA, ovalbumin; s.c., sub-
cutaneous; TCR-Tg, T cell receptor transgenic; TIL, tumor-infiltrating lymphocyte;
Trp1, tyrosinase-related protein 1; SCID, severe combined immunodeficiency.
(7). Finally, parameters that indicate immune activation in tumors
are associated with improved prognosis (8).
CD4+ VERSUS CD8+ T CELLS IN TUMOR IMMUNOLOGY
Traditionally, CD8+ T cells have been thought to be the major
mediators of effective anti-tumor T cell responses. Such a view is
supported by the pronounced cytotoxic activity of CD8+ T cells
in vitro, and the observation that tumors that escape CD8+ T cells
onslaught may have altered or downregulated MHC class I anti-
gen expression (9–11). Moreover, studies done in an MHC class
I-restricted T cell receptor (TCR) transgenic mouse showed that
CD8+ T cells, in the absence of CD4+ T cells, maintained their
anti-tumor effect (12). Despite these observations, several stud-
ies indicate limited anti-tumor effects of CD8+ T cells alone (6,
13–16).
The helper function of tumor-reactive CD4+ T cells improves
the efficacy of tumor-reactive CD8+ T cells (17–20). Similarly,
treatment of a patient with metastatic melanoma with autol-
ogous CD4+ T cells specific for the tumor-associated antigen
NY-ESO-1 resulted in sustained clinical remissions with evidence
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of endogenous immune responses against other tumor-derived
antigens (21). In support of these findings, transfection of tumor
cells with MHC class II genes resulted in increased protective
immune responses against tumors (22, 23). Collectively, these
results indicate an augmenting effect of CD4+ T cells on CD8+ T
cell responses against tumors.
On the other hand, CD4+ T cells alone, in the absence of CD8+
T cells, have also been demonstrated to eliminate tumor cells.
Thus, adoptive transfer experiments using primed CD4+ T cells
generated by immunization with tumor cells conferred protection
against a subsequent tumor challenge (24, 25). Moreover, naïve
CD4+ T cells in TCR-transgenic mice conferred protection against
tumor development upon subcutaneous (s.c.) injection of tumor
cells (26, 27). Finally, using MHC class I-molecule and MHC class
II-molecule restricted TCR-transgenic mice specific for the Dby
H–Y antigen, CD4+ T cells were found to be more efficient at
eradicating cancer cells than CD8+ T cells in a side-by-side com-
parison (28). Here, we will focus on the anti-tumor properties of
CD4+ T cells in the absence of CD8+ T cells.
PIONEERING EXPERIMENTS ON THE ROLE OF CD4+ T CELLS
IN ERADICATION OF TUMORS
The role of CD4+ T cells was initially investigated in experiments
where tumor-bearing mice were treated by adoptive transfer of
T cells obtained from syngeneic mice immunized with irradi-
ated tumor cells (25, 29), or with living tumor cells followed
by surgical resection (24). It was shown that when T cells from
tumor-immunized donors were purified prior to adoptive trans-
fer, Lyt1+ 2− (CD4+) T cells had a superior ability to cure
FBL-3 erythroleukemic tumors compared to Lyt1− 2+ (CD8+)
T cells (29). Treatment with cyclophosphamide was required for
the curative effect of CD4+ T cells to be observed. However,
in the first reported experiments (29), a role of endogenous
CD8+ T cells in the tumor-bearing host was not ruled out.
In follow-up experiments, this possibility was formally excluded
by the use of T cell deficient tumor-bearing recipients (25).
Similar results were obtained using the X5563 plasmacytoma
model (24), where transfer of purified Lyt1+ 2− (CD4+) T cells
had superior therapeutic potential. In the following decades,
experimental evidence supporting the anti-tumor properties of
tumor-specific CD4+ T cells alone has accumulated (27, 28,
30–39).
TCR-TRANSGENIC MODELS FOR CD4+ T CELL-MEDIATED
REJECTION OF TUMORS
The experiments referred to in the preceding section had features
that prohibited detailed studies of the mechanisms of CD4+ T
cell-mediated tumor protection. First, the CD4+ T cells were poly-
clonal. Second, CD4+ T cells were pre-primed cells obtained after
immunization, making it impossible to study naïve CD4+ T cells in
primary anti-tumor responses. Third, the relevant tumor-specific
antigens were often not known.
The generation of TCR-transgenic mice that recognize tumor
antigens presented on MHC class II molecules (Table 1) offered
a novel approach to bypass these difficulties. In two mod-
els, these antigens are bona fide cancer antigens; the tumor-
specific myeloma protein V region idiotype (Id) (26, 27) and the
melanoma-associated tyrosinase-related protein 1 (Trp1) (35). In
other TCR-transgenic models, the antigens are either minor his-
tocompatibility antigen Dby (H-Y) (28), viral antigens such as the
hemagglutinin (HA) (40–42), or xenogeneic proteins such as oval-
bumin (OVA) (17, 43, 44). While the transgenic TCR specific for
the mutated myeloma antigen was obtained after immunization of
mice syngeneic to the tumor (45, 46), the transgenic TCR specific
for the non-mutated antigen was obtained after immunization of
Trp1-deficient mice. Thus, in the latter model, Trp1 represents a
foreign antigen to which high-affinity TCRs are induced (due to a
lack of T cell tolerance) (35).
Table 1 |TCR-transgenic models employed in studies of anti-tumor CD4+ T cell responses.
TCR-Tg model Antigen Classification of
antigen
Antigen location MHC II
restriction
Peptide Reference
4B2A1 (λ2315) Light chain idiotype (Id) of













Marilyn (H–Y) Minor histocompatibility
antigen (Dby)
Tissue antigen Secreted, cell membrane (55, 56) I–Ab aa608–622 (47)
T2.5-5 (HA) Influenza PR8 hemagglutinin Viral antigen Varying (construct dependent)1 I–Ad aa126–138 (48)
14.3.d (HA) Influenza PR8 hemagglutinin Viral antigen Varying (construct dependent)1 I–Ed aa110–120 (49)
DO11.10 (OVA) Chicken ovalbumin Xenogeneic model antigen Varying (construct dependent)2 I–Ad aa323–339 (50)
OT-II (OVA) Chicken ovalbumin Xenogeneic model antigen Varying (construct dependent)2 I–Ab aa323–339 (51)
1Varyingly expressed by fusion to other proteins, which control cellular distribution. The viral protein, as such, localizes to the cell surface (57).
2Varyingly expressed as full-length cDNA [containing signal sequence for secretion (58)] or fused to other proteins, which control cellular distribution.
Frontiers in Immunology | Tumor Immunity April 2014 | Volume 5 | Article 174 | 2
Haabeth et al. CD4+ T cell-mediated killing of tumors
MHC CLASS II STATUS OF TUMOR CELLS USED IN TUMOR
IMMUNOLOGY STUDIES FOCUSED ON THE ROLE OF CD4+ T
CELLS
CD4+ T cells recognize peptides (about 13–17aa long) bound to
the groove of MHC class II molecules (59) on professional antigen-
presenting cells (APCs) (B cells, dendritic cells, macrophages, in
addition to thymic epithelial cells) (60–62). However, in certain
cells, MHC class II molecules may be induced by interferon gamma
(IFN-γ) stimulation (63, 64). Thus, in CD4+ T cell immune
responses to tumors, the MHC class II status of the tumor cells
is of importance. The MHC II expression status of tumor cells
used in studies with CD4+ TCR-transgenic mice is summarized
in Table 2.
DIRECT AND INDIRECT KILLING OF TUMOR CELLS BY CD4+ T
CELLS
The antigen-specific interaction between CD4+ T cells and MHC
IIPOS tumor cells is conceptually easy to grasp. On the other hand,
the basis for antigen presentation and anti-tumor effector mecha-
nisms are less obvious in the context of MHC IINEG tumors (25, 26,
31, 70) – simply because such cancer cells cannot directly stimulate
MHC class II-restricted CD4+ T cells (Figure 1). In the following
sections, we discuss mechanism of CD4+ T cell-mediated direct
killing of MHC IIPOS tumor cells and indirect killing of MHC
IINEG tumor cells. Emphasis is put on observations from TCR-
transgenic models, where the T cell specificity is known and both
naïve and primed CD4+ T cells are readily available.
Table 2 | Use ofTCR-Tg models for studies of anti-tumor CD4+ T cell immune responses.
TCR-Tg model
(antigen)






T cell source Reference
4B2A1 (λ2315) MOPC315 (plasmacytoma) No − Yes Naïve (endogenous)b (26, 27, 34, 65)
MOPC315.37c No − No Naive (endogenous) (36)
A20 (B lymphoma) Yes + Yes Naive (endogenous) (26, 33, 66)
Adoptive transfer, naive
A20 (B lymphoma)d Yes + No Naive (endogenous) (26)
7A6 (Trp1) B16/CIITA (melanoma) No +e N/D Naive (endogenous) (35)
Adoptive transfer, activated
B16 (melanoma) No +f N/D Adoptive transfer, naïve (37, 38)
Adoptive transfer, activated
Marilyn (H–Y) MB49 (bladder) No +f N/D Adoptive transfer, naive (28)
TRAMP-C2 (prostate) No − N/D Adoptive transfer, activated
βTC-TET No − N/D
WR21 (salivary gland) No − N/D
T2.5-5 (HA) AB1 (mesothelioma) Yes − N/Dg Naive (endogenous) (40)
Adoptive transfer, naive
14.3d (HA) CT26 (colon) Yes N/Dh N/Di Naive (endogenous) (41, 42)
Adoptive transfer, naive
DO11.10 (OVA) A20 (B lymphoma) Yes + N/Dj Adoptive transfer, activated (17)
A20 (B lymphoma) Yes + Nok Naive (endogenous) (44)
Adoptive transfer, activated
OT-II (OVA) EG-7 (thymoma) Yes − Yesl Adoptive transfer, activated (43)
N/D, not determined.
aEctopic antigen expression signifies that the tumor cell line was transfected for expression of the relevant antigen.
bThe designation naive (endogenous) is used to describe tumor challenge experiments in TCR-Tg mice in which no prior priming of antigen-specific T cells was
performed.
cMOPC315.37 contains a Gly15→Arg15 mutation within the λ2 gene that causes intracellular retention (67).
dCells were transfected with a mutated λ2315 variant that causes retention within the endoplasmic reticulum, precluding secretion (67).
eCells were transfected to overexpress MHC class II trans-activator (CIITA) to ensure high levels of expression of MHC II (35).
fInducible expression by interferon gamma stimulation.
gOnly cell surface expression was tested (40).
hA previous publication reports constitutive MHC II expression in vitro (68).
iCells were transfected with HA fused to EGFP. Only surface expression was tested (41).
jSecretion expected; cells were transduced with constructs containing the full-length OVA cDNA sequence, which contains signal element for secretion (58).
kCells were transfected with OVA fused to the trans-membrane domain of transferrin receptor, causing membrane expression (44).
lEarlier report demonstrates secretion from the same cell line (69).
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FIGURE 1 | Direct and indirect killing of tumor cells by CD4+ T cells.
(A) CD8+ T cells can directly kill tumor cells that express MHC class I
molecules, whereas (B) cytotoxic CD4+ T cells can kill tumor cells that
express MHC class II molecules. (C) While most tumor types express MHC
class I molecules, they often lack expression of MHC class II. How do CD4+ T
cells recognize and eliminate MHCIINEG tumor cells? (D) CD4+ T cells may kill
MHC class II negative (MHC IINEG) tumors by a mechanism where (i) tumor
antigen secreted by tumor cells is processed and presented by MHCIIPOS
macrophages to CD4+ T cells. (ii) Bi-directional interaction/activation of
macrophages and CD4+ T cells (iii) activates tumoricidal macrophages that in
turn kill the tumor cells (In addition, activated CD4+ T cells themselves could
possibly directly kill tumor cell in a TCR/MHC II-independent manner.).
DIRECT KILLING OF MHC CLASS IIPOS TUMOR CELLS
The existence of CD4+ T cells with cytotoxic properties has been
increasingly recognized throughout the last three decades. Such
cells are thought to function in a fashion analogous to cytotoxic
CD8+ T cells, with antigen recognition triggering the release of
cytotoxic mediators. CD4+ T cells displaying direct cytotoxicity
in vitro toward MHC IIPOS targets, including tumor cells, have
been described by several authors (37, 45, 70, 71). Correspond-
ingly, efficient elimination of MHC IIPOS tumors by T cells with
such properties is also observed in vivo (26, 28, 33, 35, 37, 38, 72).
Several effector mechanisms have been implicated for tumor-
specific cytotoxic CD4+ T cells. In a model of Id-specific CD4+ T
cell responses against an MHC IIPOS B lymphoma, in vitro cyto-
toxicity was shown to be dependent on signaling mediated by
binding of Fas ligand (FasL) on CD4+ T cells to the death recep-
tor Fas on tumor cells (66). Naïve T cells showed little killing
activity, whereas Th1 differentiation greatly enhanced cytotoxic-
ity. However, in vivo elimination of tumor cells was not affected in
FasL-deficient (gld−/−) Id-specific TCR-Tg mice, suggesting that
signaling through the Fas pathway is dispensable for tumor killing
and that additional mechanisms are operational in vivo (66).
Indeed, if the tumor antigen is secreted as is the case in the studies
of Lundin et al. (33, 66), the indirect mechanism via Th1/M1
macrophages described below could also be active, and might
play a prominent role in tumor rejection. In the Trp1-specific
TCR-transgenic model, it was demonstrated that the rejection of
B16 melanoma cells was abrogated in mice deficient for either
granzyme B or perforin, indicating that these molecules are impor-
tant for CD4+ T cell-mediated killing of MHC IIPOS tumor cells
(37). In summary, different MHC IIPOS tumors may vary in sus-
ceptibility to various effector mechanisms of CD4+ T cells, as
indicated by the observations addressed above.
INDIRECT KILLING OF MHC CLASS IINEG TUMOR CELLS
In general, antibody-secreting plasma cells are MHC class II neg-
ative due to silencing of the MHC Class II trans-activator (CIITA)
occurring during plasma cell differentiation (73, 74). Multiple
myeloma (MM) is the malignant counterpart of plasma cells and
usually express little if any MHC class II molecules. MHC class
II negativity due to loss of CIITA expression appears to be a
stable phenotype, although some studies have reported MHC II
upregulation in MM cells exposed to retinoic acid (75) or IFN-γ
(76, 77).
The work of our research group is based on experiments using
the mineral oil-induced BALB/c plasmacytoma (MOPC)315 (52,
70). MOPC315 cells secrete a highly mutated and unique mono-
clonal IgA (myeloma protein). The λ2 light chain of the myeloma
protein contains somatic mutations in positions 38, 50, 94, 95, and
96 that are unique to MOPC315 (78). Thus, the myeloma protein
light chain is referred to as λ2315 (Figure 2A).
By immunization of BALB/c mice with free λ2315 L chain,
known from previous studies to stimulate T cells (81), I-
Ed-restricted, Id-specific CD4+ T cell clones were generated
(Figure 2A) (45). These clones recognize a unique Id-epitope,
which depends on the somatic mutations in codons 94, 95, and 96
within the CDR3 loop of the λ2315 light chain (79). As would
be expected, MOPC315 derived λ2315-immunoglobulin has to
be endocytosed and processed by APCs prior to MHC class II
presentation of the Id-peptide (80).
MOPC315 is found to be MHC class II negative by a number
of criteria: (i) Negative staining with anti-MHC class II antibodies
both in vitro, ex vivo (70), and in vivo (65). Lack of expression
of MHC II molecules on MOPC315 was independently reported
by others (82). (ii) Exposure to high amounts (500 ng/ml) of
IFN-γ IL-4, or supernatant from activated Th1 cells, all failed to
induce any detectable expression of MHC class II in vitro (70).
(iii) Both in vitro-cultured (70) and ex vivo (65) MOPC315 cells
failed to stimulate Id-specific MHC class II-restricted T cells in
proliferation and cytokine secretion assays.
IDIOTYPE-SPECIFIC CD4+ T CELL CLONES INDUCE KILLING
OF MHC CLASS II NEGATIVE MYELOMA CELLS
IN VITRO – BUT ONLY IN THE PRESENCE OF
MHC-COMPATIBLE APCs
A weak cytotoxicity that was greatly augmented by addition of high
amounts of myeloma protein was observed when Id-specific CD4+
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FIGURE 2 |The MOPC315 myeloma model. Naïve tumor-specific CD4+ T
cells protect against MHC IINEG tumor challenge in the absence of other T
cells and B cells. (A) MOPC315 myeloma cells of BALB/c origin secrete an
IgA M315 myeloma protein with a mutated λ2 light chain referred to as
λ2315. M315 is endocytosed and processed by BALB/c APCs, and a CDR3
sequence that includes residues 91–101 of λ2315 is presented on the MHC
class II molecule I-Ed to Id-specific CD4+ T cells. The peptide that is
recognized by Id-specific CD4+ T cells contains somatic mutations in
positions 94, 95, and 96 (45, 79, 80). Based on the αβTCR of the
Id-recognizing 4B2A1 clone, a TCR-transgenic mouse was generated (46).
Most CD4+ T cells in this mouse express a transgenic TCR that can be
tracked by a clonotype-specific mAb [Nomenclature: antigenic
determinants in immunoglobulin variable (V) regions are called idiotopes
(Id). The 91–101 peptide is thus an Id-peptide, and the CD4+ T cells that
recognize this Id-peptide presented by I-Ed are called Id-specific].
(B) Id-specific TCR-transgenic mice on an immunosufficient background
(BALB/c) are resistant to a challenge with IdPOS MOPC315 cells but
succumb to IdNEG J558 myeloma cells [reproduced with permission from
Proc Natl Acad Sci (26), Copyright 1994 National Academy of Sciences,
U.S.A.]. (C). Id-specific TCR-transgenic mice on an immunodeficient
background (SCID), lacking other T and B cells than Id-specific CD4+ T
cells, are also resistant to MOPC315 tumor development [reproduced with
permission from Immunity (34)]. Tumor resistance could be transferred
with purified Id-specific CD4+ T cells to SCID mice (27).
T cells were co-cultured with MHC-compatible spleen cells from
BALB/c (H-2d) MHC IINEG MOPC315. Importantly, MHC II
incompatible spleen cells from C57BL/6 failed to support cytotox-
icity (70). Moreover, the cytotoxic effect could not be transferred
by supernatants of activated T cells. It was suggested that some of
the spleen cells, e.g., macrophages (Mφ) stimulated by activated
T cells, were important as cytotoxic effector cells in the in vitro
cultures (70).
NAÏVE Id-SPECIFIC CD4+ T CELLS IN T CELL RECEPTOR
TRANSGENIC MICE PROTECT AGAINST Id+ MYELOMA
CELLS IN THE ABSENCE OF CD8+ T CELLS AND B CELLS
To facilitate studies of the role of Id-specific CD4+ T cells in
tumor protection against MHC II negative MOPC315, an Id-
specific TCR-transgenic mouse on syngeneic BALB/c background
was established (46).
In initial experiments, naïve Id-specific T cells from TCR-
transgenic mice did not respond to MOPC315 in vitro. Despite
this, Id-specific TCR-transgenic mice were specifically protected
against s.c. challenge with MOPC315 cells (26) (Figure 2B). Erad-
ication of MOPC315 cells resulted in a change of T cell phenotype,
since T cells of surviving TCR-transgenic mice had increased cyto-
toxicity against Id+MHC IIPOS B lymphomas, and since they upon
stimulation produced much IFNγ and some IL-4.
By breeding the TCR-Tg mice onto a SCID background, it
was demonstrated that rejection of MOPC315 was independent
of CD8+ T cells and B cells/antibodies (27, 34) (Figure 2C). Addi-
tionally, tumor protection could be transferred to SCID mice with
adoptive transfer of purified Id-specific CD4+ T cells (27).
Id-PRIMED APC CAN BE DETECTED IN TUMOR TISSUE OF
LARGE ESTABLISHED MYELOMAS
The finding that naïve CD4+ T cells could initiate rejection of a
MHC II negative tumor indicated that host cells expressing MHC
class II molecules were responsible for the presentation of Id to
CD4+ T cells. In a subsequent study, it was demonstrated that s.c.
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MOPC315 tumors contained APCs that were able to stimulate Id-
specific CD4+ T cells in vitro in an MHC-restricted manner (65).
The great majority of MHC IIPOS tumor-infiltrating APCs were
CD11b+CD11cLOWCD80+CD86+. These studies demonstrated
that MHC class II negative MOPC315 tumors were infiltrated with
Id-primed APCs with macrophage-like characteristics.
Id-SPECIFIC CD4+ T CELLS ARE PRESENT AND ACTIVATED IN
TUMOR TISSUE
Given that Id-primed APC could be demonstrated in MOPC315
tumors, it was investigated if Id-specific CD4+ T cells were also
present, and whether they were activated. In these experiments, a
high amount of MOPC315 cells were injected in order to overcome
the resistance of TCR-transgenic mice. A number of observations
indicated that Id-specific CD4+ T cells were specifically activated
in small s.c. MOPC315 tumors established in Id-specific TCR-
transgenic mice: (i) The CD4+/CD8+ ratio was skewed toward
CD4+ in tumor tissue. (ii) CD4+ blasts within the tumor were
selectively enriched for cells expressing the Id-specific TCR. (iii)
Id-specific CD4+ tumor-infiltrating lymphocytes (TIL) were acti-
vated (CD69+ CD25+), and proliferated (BrdU+) in clusters
associated with MHC IIPOS tumor-infiltrating APC (65).
SECRETION OF TUMOR-SPECIFIC ANTIGEN IS REQUIRED FOR
CD4+ T CELL-MEDIATED REJECTION OF MHC IINEG TUMORS
While it was clear that tumor-infiltrating APCs and lymph node
cells take up the λ2315 antigen and display the Id-peptide on MHC
class II molecules (34, 65), the precise source of the priming Id
antigen was not established. To address this question, we used two
secretory variants of MOPC315: one that secretes the complete
M315 myeloma protein composed of αH chain and λ2315 L chain
(MOPC315), and another that only secrets the free λ2315 L chain
(MOPC315.26). In addition, we used two non-secretory variants:
one where the free λ2315 L chain is retained intracellularly due
to a point mutation (MOPC315.37) and another where no Ig is
produced (MOPC315.36) (67, 83).
When Id-specific TCR-transgenic SCID mice were challenged
with the four variants, protection was observed for the λ2315-
secreting variants MOPC315 and MOPC315.26, while there was
no protection against the antigen-negative MOPC315.36. Tumor
take was significantly delayed, but still complete, in mice chal-
lenged with the MOPC315.37, which retains λ2315 intracellu-
larly. This result was surprising since in MOPC315.37-containing
Matrigels, macrophages were MHC IIHI, and Id-specific T cells
were activated (CD69+). The only striking deficiency observed
with MOPC315.37 in vivo was deficient T cell activation in drain-
ing lymph nodes, presumably due to poor local availability of the
intracellularly retained tumor antigen. These results indicate that
the extracellular concentration of secreted tumor-specific antigen
is important for protection against an MHC IINEG tumor, most
likely due to enhanced priming of APCs in draining lymph nodes
as well as macrophages in tumors (36, 84).
DETECTION OF TUMOR-SPECIFIC CD4+ T CELLS AND
MACROPHAGES IN EARLY STAGES AFTER TUMOR CELL
CHALLENGE: THE MATRIGEL METHOD
To study local events at the injection site at the early stages of
the anti-tumor immune response, we injected the tumor cells sus-
pended in a Matrigel solution (Figures 3 and 4). Matrigel is a liquid
basement membrane preparation that jellifies rapidly at body tem-
perature. Thus, a tumor bed of a defined size was generated that
could be isolated and assayed to characterize infiltrating cells at any
time point following tumor cell injection (Figure 3). Moreover,
the defined volume of the gel plug allows quantitative assays of
secreted factors within the tumor microenvironment (39). Initial
experiments demonstrated that tumor cells embedded in Matrigel
were rejected by TCR-transgenic SCID mice, although less effi-
ciently than in the absence of Matrigel (34). Thus, events in the
tumor cell-containing Matrigel most likely reflected those taking
place during successful immunosurveillance of MHC II negative
tumor cells by CD4+ T cells.
Using this system, a longitudinal characterization of the
immune response within the tumor microenvironment and drain-
ing lymph nodes was undertaken (34, 36, 39, 85). The findings
are summarized in Figure 4. Briefly, secreted myeloma protein
is presented by APC in tumor-draining lymph nodes to Id-
specific CD4+ T cells. Upon recognition, T cells are activated,
polarize into Th1 cells, and migrate to the Matrigel/tumor. In
FIGURE 3 |The Matrigel assay. A novel approach to unravel the dynamics of
CD4+ T cell-mediated primary anti-tumor immune responses. At day 0,
subcutaneous injections with MOPC315 tumor cells suspended in liquid
Matrigel. When the Matrigel solution reaches body temperature, it jellifies and
forms a plug containing the tumor cells. At various time points after injection
(n days), the Matrigel plug and tumor-draining lymph nodes are dissected out
and analyzed ex vivo for cellular content, function of cells, and cytokines (34,
36, 39, 85).
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FIGURE 4 | Mechanism of rejection of MHCIINEG myeloma cells by
Id-specific CD4+ T cells. The following events are based on experiments
where Id-secreting MOPC315 suspended in liquid Matrigel was injected
subcutaneously in TCR-transgenic mice. (i–viii). (i) At the incipient tumor
site, macrophages [CD11b+, CD11c−, CD80/CD86+ MHC IILO, F4/80+] start
to infiltrate the tumor/Matrigel from day +1. Tumor-infiltrating macrophages
become Id-primed by extracellular myeloma protein by the conventional
MHC II presentation pathway (65). (ii) Extracellular Id+ myeloma protein (or
possibly Id-primed tumor APCs) drain to lymph nodes where Id-primed
APCs stimulate Id-specific CD4+ T cells. Uncertainties as to the mechanism
of Id+ Ag draining and the identity of Id-primed APCs are indicated by a
question mark (?). (iii) Id-specific CD4+ T cells become activated by day +3,
are substantially expanded by day +6 (34), and polarize into Th1 cells by day
+8 (39, 85). Upon activation in the tumor-draining lymph node, a number of
molecules are significantly upregulated on the surface of the Id-specific
CD4+ T cells, while some are consistently downregulated (85). (iv) Activated
CD4+ T cells (CD62LLOW) leave the lymph node and accumulate at the tumor
site from day +6 (34, 86). (v) At the incipient tumor site, infiltrating
Id-specific CD4+ T cells are re-activated by Id-primed macrophages (34).
(vi) Moreover, in addition to a sustained Th1 phenotype, the
tumor-infiltrating CD4+ T cells dramatically change expression of a number
of surface molecules (85). Several molecules are upregulated on both
activated CD4+ T cells in the tumor-draining lymph node, and on
tumor-infiltrating CD4+ T cells, although at higher levels in the latter
population. (vii) IFN-γ produced by tumor-infiltrating Th1 cells activates
macrophages that up-regulate MHC class II on the cell surface and show
increased expression of M1-associated surface molecules (34, 39).
IFN-γ-activated macrophages acquire a tumoricidal phenotype with the
upregulation of cytotoxicity-associated markers including granzyme A/B,
and NKG2D (39). In addition, purified activated macrophages can directly
inhibit myeloma growth in vitro (34, 36, 39). The mechanisms underlying M1
macrophage-mediated growth inhibition is unknown, but once the
macrophages are activated the growth inhibition is antigen independent
(36). (viii) Analysis by gene expression profiling and Luminex multiplex
cytokine analyses has revealed that the Id-specific CD4+ Th1-mediated
anti-tumor immune response has a striking resemblance to the
characteristics of acute inflammatory responses (39). Thus, we propose that
Th1-mediated inflammatory responses may protect against cancer (87).
the Matrigel/tumor, Th1 cells become re-activated by tumor-
infiltrating macrophages that has endocytosed and processed
myeloma protein. Th1 derived IFN-γ activates macrophages into
tumoricidal M1 macrophages (34, 36, 39, 65).
UNRESOLVED ISSUES AND DIRECTIONS FOR FUTURE
RESEARCH
USE OF MHC CLASS II NEGATIVE TUMOR CELL LINES IN TUMOR
IMMUNOLOGY
While MHC class II positivity in tumor cells is generally to be
trusted, MHC class II negativity should, for obvious reasons, be
viewed with a healthy skepticism. In the case of MOPC315, many
attempts by others and us have consistently failed to detect expres-
sion of MHC class II molecules in vitro as well as in vivo, even
when MOPC315 cells were exposed to IFN-γ (34, 70, 82, 88). In
several other models, such as the use of the erythroleukemia cell
line FBL-3 (25), the UV-induced fibrosarcoma 6132A-PRO (31),
and the methylcholanthrene-induced Mc51.9 (32); no MHC class
II was detected on tumor cells even after IFN-γ exposure, similar
to MOPC315. In the B16 melanoma model, Quezada et al. showed
that the cell line used in their experiments expressed MHC class
II, but only when the tumor-bearing hosts were subjected to a
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combination of irradiation and adoptive transfer of Trp1-specific
CD4+ T cells together with anti-CTLA mAb (37). Xie et al. also
reported that B16 cells express MHC class II by immunofluores-
cence staining of tumor biopsies, but the identity of the MHC
class IIPOS cells within the sections was not further character-
ized, complicating interpretation (38). In contrast, Hung et al.
reports the use of B16 tumor cells that were described to be MHC
IINEG (30).
Peres-Diez et al. (28) reported that expression of MHC class II
molecules on tumor cells was not required for rejection mediated
by CD4+ cells. In note, they found that: H-2k H-Y+ tumor cells
were rejected by I–Ab-restricted, H–Y-specific CD4+ T cells in an
immunodeficient H-2b mouse. An alternative approach to ensure
the absence of the relevant MHC class II molecule in a tumor cell
line would be to delete the corresponding MHC class II molecule
genes from the tumor cells.
IS SECRETION OF TUMOR-SPECIFIC ANTIGEN BY MHC IINEG TUMORS
REQUIRED?
The tumor-specific antigen used in our own studies, the MOPC315
myeloma protein, is a highly secreted antigen, with serum lev-
els reaching milligrams per milliliter levels. Concentrations of
myeloma protein in tumor tissues would be expected to be even
higher. Surprisingly, a non-secreting myeloma variant that only
expresses an intracellularly retained mutated Id+ L chain, but
in high amounts, was not rejected (36). In the absence of suf-
ficient tumor antigen secretion, it might be expected that either
spontaneous necrosis or apoptosis of tumor cells containing such
high amounts of intracellular tumor antigen could prime tumor-
infiltrating APC with tumor-specific antigen. This is apparently
not the case for the non-secreting variant of MOPC315. It remains
to be seen whether cytotoxic drug treatment of mice with tumors
caused by this particular MOPC315 variant could enhance Id
priming of APCs via uptake of necrotic or apoptotic cells.
In other MHC IINEG models where tumor cells is reported to be
rejected by CD4+ T cells (28, 31, 32), there is scarce information
as to whether tumor-specific antigen is secreted or not (Table 2).
In the case of H-Y antigen, which clearly must be transferred from
the tumor cells to host APC for MHC II presentation (28), there
is little information about the extent of secretion of the antigen.
In yet other cases, the tumor-specific antigen is simply not known
(25), precluding any analysis of secretion status. It should fur-
ther be noted that in some experiments [e.g., Ref. (24, 25, 37)] it
has not been rigorously excluded that non-malignant normal cells
could also produce the “tumor-specific” antigen. This possibility
is virtually excluded in the MOPC315 model since CD4+ T cells
recognize a somatically mutated tumor-specific antigen unique to
MOPC315 myeloma cells. By and large, it appears that secretion of
tumor-specific antigen facilitates priming of host APC and stimu-
lation of CD4+ T cells. However, it is possible that the requirement
of secretion could vary for distinct tumors and tumor-specific
antigens, perhaps related to differences in susceptibility for cross-
presentation of antigen associated with either necrotic or apoptotic
tumor cells, or secreted vesicles such as exosomes.
What about MHC IIPOS tumors – do they also require secretion
of tumor-specific antigen? For MHC IIPOS B lymphoma, a trans-
fectant that secretes λ2315 was rejected, while another transfectant
expressing a mutated intracellularly retained λ2315 was not (26).
Similarly,A20 cells expressing HA, which apparently was negligibly
secreted since HA was not found in serum, was not rejected (89).
The Dby minor histocompatibility antigen (H–Y) (28) and Trp1
(35, 37, 38) have both been reported to be secreted by tumor cells.
A strategy to test the hypothesis that secretion of tumor-specific
antigen is required for rejection of MHC IIPOS tumors would be
to transfect MOPC315.37 with CIIITA so that the tumor cells
become MHC IIPOS. If this transfectant is rejected in Id-specific
TCR-transgenic mice, this would weaken the hypothesis.
BY WHICH PATHWAY IS TUMOR ANTIGEN PRESENTED BY APC IN
DRAINING LYMPH NODES?
In the tumor models where it has been tested, be they MHC IINEG
(28, 34, 65) or MHC IIPOS (37, 38), there was an apparent need for
tumor-specific antigen to be presented by host APC to stimulate
naïve (but not memory) CD4+ T cells. Thus, in the case of the
B16 MHC IIPOS model, no rejection by naïve Trp1-specific CD4+
T cells was obtained in hosts that lacked MHC class II molecules.
By contrast, transfer of CD4+ T cells that first had been primed
in vitro could readily reject B16 tumors (37, 38). These findings
indicate that MHC IIPOS tumor cells themselves are incapable of
stimulating naïve Trp1-specific CD4+ T cells, and that priming
by professional host APC is required. In addition, experiments
reported by Xie et al. (38) using Trp1-deficient mice indicate that
Trp1 derived from host tissue is redundant for priming APC and
that Trp1 derived from B16 tumor cells suffice, at least for stimula-
tion of memory CD4+ T cells. It is still, however, unclear how the
Trp1 antigen is transferred from tumors to host APC, and in which
anatomical compartment priming of CD4+ T cells take place.
The conclusions of the above experiments are supported by
previous observations in the MOPC315 model, which directly
demonstrate activation of Id-specific CD4+ T cells in draining
lymph nodes (34, 36, 85). Moreover, treatment with the sphin-
gosine phosphate receptor modulator fingolimod that abrogates
egress of T cells from lymph nodes led to a decreased number
of Id-specific CD4+ T cells within the tumor, resulting in failure
of tumor rejection (86). Consistent with these findings, the non-
secreting MOPC315.37 variant caused little activation of CD4+ T
cells in draining lymph nodes, and tumor rejection did not occur.
Idiotype-primed APCs are readily found in lymph nodes that
drain MOPC315 tumors (Dembic and Bogen, unpublished exper-
iments). It should therefore be possible by cell purifications and
characterizations to reveal the identity of these Id-primed APCs
in lymph nodes. Information from such experiments could help
to define the mechanisms by which APC get primed by secreted
tumor antigen. For example, if the predominant features of Id-
primed APCs are that of a residential dendritic cell, this may signify
priming by soluble antigen arriving to the lymph node via afferent
lymphatic vessels.
ELIMINATION OF MHC IINEG TUMOR CELLS
It is well documented that Th1/IFN-γ-activated M1 macrophages
isolated from tumors under conditions of tumor rejection can
directly inhibit the growth of MHC IINEG myeloma cells in vitro
(34, 36, 39). However, the molecular mechanisms mediating the
inhibition of tumor cell growth remain to be established. Possibly,
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reactive oxygen species could be of importance, since resistance
against B16 cells [although in later work reported to be MHC class
IIPOS under conditions of rejection (37)] was reduced in iNOS−/−
and NOX2−/− mice (30). Results of Perez-Diez et al. indicate that
under some circumstances, NK cells activated by CD4+ T cells
are important, but the effector mechanisms employed by such NK
cells have not been addressed (28).
It is also possible that CD4+ T cells could themselves directly kill
tumor cells, e.g., through FasL/Fas interactions, similar to what has
been described for killing of MHC IIPOS B lymphoma cells (33),
or a perforin/granzyme B-dependent mechanism as described for
killing of the MHC IIPOS B16 cells (37). The efficacy of killing
mechanisms of CD4+ T cells could also differ for different tumors.
Thus, even though Th1 cells efficiently killed transfected A20 cells
in vitro by a FasL-dependent mechanism, the same cells could not
kill MOPC315 (26, 66). Finally, it has been reported that IFN-γ
produced by tumor-specific Th1 cells mediate tumor rejection
by means of angiostatic effects, thus causing starvation of the
tumor (32).
DO CD4+ T CELL-MEDIATED IMMUNE RESPONSES AGAINST MHC IINEG
TUMOR CELLS CONVEY BYSTANDER KILLING OF TUMOR CELLS THAT
HAVE LOST EXPRESSION OF ANTIGEN?
In theory, macrophage-mediated killing of MHC IINEG tumors
could be expected to indiscriminately kill surrounding cells,
including tumor cells that have lost expression of antigen
(“bystander killing”). If true, this would be a clinically impor-
tant asset of Th1/M1 macrophage-mediated killing of tumor cells
(34, 36, 39). The previously described angiostatic properties of
Th1 derived IFNγ (32) would also be expected to cause bystander
killing. On the other hand, direct killing of MHC IIPOS tumor
cells by cytotoxic CD4+ T cells was demonstrated not to induce
bystander killing (37).
WHAT CD4+ T CELL PHENOTYPES SUPPORT ANTI-TUMOR IMMUNITY?
Naïve CD4+ T cells in Id-specific TCR-transgenic mice, which
eradicate injected MHC IINEG tumor cells, develop into IFNγ-
secreting Th1 TILs that induce macrophage polarization into
tumoricidal M1 macrophages (33, 34, 39). Transfer of naïve Id-
specific CD4+ T cells could cure established MHC IIPOS tumors
(33). In the Trp1-specific TCR-transgenic model, naïve (37, 38),
Th1 (35), and Th17 (35) cells have been demonstrated to eradicate
MHC IIPOS tumors. Collectively, these results indicate that the pri-
mary anti-tumor response of naïve CD4+ T cells is followed by
T cell differentiation into Th1 (or possibly Th17) cells that confer
anti-tumor immunity irrespective of MHC class II expression on
tumor cells. While Th1 cells are clearly associated with anti-tumor
immunity, variable effects have been observed with other CD4+
T cell subsets, reviewed in Ref. (90). Moreover, recent studies sug-
gest that effector CD4+ T cells retain some degree of functional
plasticity (91, 92). The plasticity of effector Th populations may
explain the differential effects of the various Th cell populations in
tumor immunity. In addition, exploiting the plasticity of Th cell
subsets may be utilized in immune therapy.
TOLERANCE INDUCTION OF TUMOR-SPECIFIC CD4+ T CELLS
Use of TCR-transgenic mice offers the possibility of studying
tolerance development by following the fate and function of
tumor-reactive CD4+ T cells. When Id-specific TCR-transgenic
mice failed to reject high amounts of injected MHC IINEG
MOPC315 cells, CD4+ T cells in peripheral lymphoid organs and
in the tumor became deleted (93). The extent of deletion became
more profound as tumor size increased. The deletion of periph-
eral tumor-specific CD4+ T cells seen in this model for a highly
secreted tumor antigen resembles that of exhaustion observed in
chronic viral diseases. In addition to peripheral deletion of Id-
specific CD4+ T cells, progressive MOPC315 tumors also caused
thymocyte deletion. It was demonstrated that circulatory myeloma
protein gained access to the thymus and was presented in an MHC
class II context by thymic APCs, thus causing negative selection of
thymocytes (94).
In a recent paper, T cell characteristics in Trp1-specific TCR-
transgenic mice developing B16 tumor recurrence following
adoptive therapy were studied. Recurrence was associated with
increased FoxP3+ Treg cell numbers, and increased expression of
inhibitory ligands, including PD-1 and CTLA-4 inhibitory recep-
tors on both Treg and effector CD4+ cells (95). Tumor recurrence
could be prevented by concomitant depletion of Tregs and admin-
istration of checkpoint blockade antibodies. Collectively, these
results indicate that CD4+ T cells must eliminate tumor antigen-
secreting tumor cells efficiently within a short timeframe. If the
elimination is incomplete, T cell tolerance is induced by multiple
mechanisms.
It has been shown that MHC IIPOS A20 cells, are not rejected
after i.v. injection in HA-specific TCR-transgenic mice, but induce
anergy in CD4+ T cells via priming of bone marrow derived APCs
(89, 96). Interestingly, when presentation by bone marrow derived
APCs was prevented by the use of bone marrow chimeras, anergy
did not occur, and tumor cells were rejected (72). Thus, it might
seem that tumor cells that poorly secrete tumor antigen could favor
anergy development by induction tolerogenic APCs. The above
results are consistent with previous observations that A20 cells
expressing a non-secreted λ2315 were not rejected in Id-specific
TCR-transgenic mice (26) (although it was not tested if anergy
was induced). These results, obtained with non-secreting MHC
IIPOS A20 transfectants in two different TCR-transgenic models,
are in support of the notion that tumor-specific antigen, perhaps
via presentation of apoptotic or necrotic tumor cells by a spe-
cial type of APC, favor induction of T cell anergy. In contrast,
secretion of tumor-specific antigen and presentation (perhaps by
another type of host APCs) in lymph nodes, may favor induction
of potent primary anti-tumor CD4+ T cell responses.
DICHOTOMOUS ROLE OF Th CELLS IN B CELL CANCERS
This review paper has focused on CD4+ T cell-mediated erad-
ication of tumor cells. However, CD4+ T cells may also induce
tumors. This dichotomy may especially apply to B cell tumors
since B cells are known to proliferate in response to help from
CD4+ T cells. Extensive and prolonged B cell proliferation could
indeed predispose to genetic instability and malignant transfor-
mation. In fact, B lymphoma development has been associated
with continuous antigenic exposure in chronic infectious diseases
caused by Helicobacter pylori, EBV, and hepatitis C. Moreover,
chronic immune responses to self antigens in autoimmune dis-
eases such as systemic lupus erythematosus, Sjögren’s syndrome
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and rheumatoid arthritis have also been linked to development of
B cell lymphomas, reviewed in Ref. (97, 98). Further supporting
a role for chronic antigen stimulation, diffuse large B cell lym-
phomas (98, 99) and follicular B cell lymphomas (98, 100, 101)
are frequently infiltrated with T cells. In Ig- and TCR-transgenic
mice, chronic stimulation of Id+ B cells by Id-specific CD4+
Th2 cells results in the induction of Id+ B lymphomas (102).
Moreover, two separate studies have shown that proliferation of B
lymphomas (103) and MM (104) was augmented by the presence
of CD4+ T cells.
The MOPC315 model, reviewed herein, was used in the exper-
iments were Id+ lymphomas were induced. Interestingly, when
such induced lymphoma cells were injected s.c into naïve Id-
specific TCR-transgenic mice, the lymphoma cells were promptly
rejected (102). Thus, Id+ B lymphoma cells were eliminated by
mice having naïve CD4+ T cells with an identical Id-specific TCR
to that of the B lymphoma-inducing Th2 cells. If naïve T cells
in the protected mice differentiated into tumor-eliminating Th1
cells was not investigated. However, analogous experiments indi-
cate that Th1 is the primary response to subcutaneously inoculated
B lymphomas (34, 39). These results suggest that B lymphoma cells
induced by Th2 cells are rejected by Th1 cells expressing an iden-
tical TCR. The finding has obvious implications for T cell therapy:
if a B cell tumor is initiated by Th2 cells, it may be treated by Th1
cells of the same specificity (and possibly vice versa). The same
may apply to other combinations of Th cells such as Th17/Th1
etc. Thus, re-education of T cell phenotype may become part of
the tumor immunotherapy armamentarium. Given the plasticity
of CD4+ subsets (91, 92), such re-education may become a real
possibility.
CONCLUDING REMARKS
HOW DISPARATE ARE THE MECHANISMS FOR REJECTION OF MHC IIPOS
AND MHC IINEG TUMORS?
The data reviewed herein suggest that the difference between direct
and indirect killing of tumors relates predominantly to the effec-
tor stage of tumor cell killing. Thus, CD4+ T cells can kill MHC
IIPOS cells directly, while killing of MHC IINEG occurs indirectly
via macrophages or possibly NK cells, angiostatic effects, or all of
these. In contrast, the primary activation of naïve tumor-specific
CD4+ T cells appears to be similar for the direct and indirect
mechanisms, in that presentation of tumor-specific antigen by
host APC seems to be required. However, the evidence for this in
the context of MHC IIPOS tumors is largely circumstantial. In an
MHC IINEG myeloma model, secretion of tumor-specific myeloma
protein clearly facilitates priming of APC in lymph nodes and
stimulation of naive CD4+ T cells that subsequently infiltrate the
tumor site. Thus, the nature of the antigen, by virtue of its cellular
localization and accessibility to APCs, might determine the ability
of the antigen to serve as an efficient tumor-specific antigen in
CD4+ T cell responses. A more in-depth analysis of such factors
might be of value in reconciling observations made in the various
TCR-transgenic models.
ACKNOWLEDGMENTS
The authors would like to thank everyone in Bogen lab who, over
the years, have contributed to the work described in this review.
The work has been generously supported by the Norwegian Can-
cer Society, The Multiple Myeloma Research Foundation, The
Research Council of Norway, The South-Eastern Norway Regional
Health Authority, and numerous funds and legacies mentioned
in the original research reports. The authors apologize for any
omissions of publications that could not be included due to space
constraints.
REFERENCES
1. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J
(1957) 1:779–86. doi:10.1136/bmj.1.5022.779
2. Thomas L. Discussion in Cellular and Humoral Aspects of the Hypersensitive
State. New York: Hoebner-Harper (1959). p. 529–32.
3. Burnet FM. The evolution of bodily defence. Med J Aust (1963) 2:817–21.
4. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res
(1970) 13:1–27.
5. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive
immunity maintains occult cancer in an equilibrium state. Nature (2007)
450:903–7. doi:10.1038/nature06309
6. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber
DJ, et al. Cancer regression and autoimmunity in patients after clonal repop-
ulation with antitumor lymphocytes. Science (2002) 298:850–4. doi:10.1126/
science.1076514
7. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modu-
lation in cancer with antibodies. Annu Rev Med (2013). doi:10.1146/annurev-
med-092012-112807
8. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of can-
cer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity (2013) 39:11–26. doi:10.1016/j.immuni.2013.07.008
9. Khong HT, Restifo NP. Natural selection of tumor variants in the gen-
eration of “tumor escape” phenotypes. Nat Immunol (2002) 3:999–1005.
doi:10.1038/ni1102-999
10. Garrido F, Cabrera T, Aptsiauri N. “Hard” and “soft” lesions underlying the
HLA class I alterations in cancer cells: implications for immunotherapy. Int
J Cancer (2010) 127:249–56. doi:10.1002/ijc.25270
11. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ,
et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer
immunoediting. Nature (2012) 482:400–4. doi:10.1038/nature10755
12. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, et al.
Eradication of established tumors by CD8+ T cell adoptive immunotherapy.
Immunity (2000) 13:265–76. doi:10.1016/S1074-7613(00)00026-1
13. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, et al.
Increased vaccine-specific T cell frequency after peptide-based vaccination cor-
relates with increased susceptibility to in vitro stimulation but does not lead to
tumor regression. J Immunol (1999) 163:6292–300.
14. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian
SL, et al. A phase I study of nonmyeloablative chemotherapy and adop-
tive transfer of autologous tumor antigen-specific T lymphocytes in patients
with metastatic melanoma. J Immunother (2002) 25:243–51. doi:10.1097/
00002371-200205000-00007
15. Peterson AC, Harlin H, Gajewski TF. Immunization with melan-A peptide-
pulsed peripheral blood mononuclear cells plus recombinant human
interleukin-12 induces clinical activity and T-cell responses in advanced
melanoma. J Clin Oncol (2003) 21:2342–8. doi:10.1200/JCO.2003.12.144
16. Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P. Human T
cell responses against melanoma. Annu Rev Immunol (2006) 24:175–208.
doi:10.1146/annurev.immunol.24.021605.090733
17. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, et al.
Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in
tumor eradication in vivo. J Exp Med (1999) 190:617–27. doi:10.1084/jem.
190.5.617
18. Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ.
Antigen-specific CD4+ T-cell help is required to activate a memory CD8+
T cell to a fully functional tumor killer cell. Cancer Res (2002) 62:6438–41.
19. Janssen EM, Lemmens EE,Wolfe T, Christen U,Von Herrath MG, Schoenberger
SP. CD4+ T cells are required for secondary expansion and memory in CD8+
T lymphocytes. Nature (2003) 421:852–6. doi:10.1038/nature01441
Frontiers in Immunology | Tumor Immunity April 2014 | Volume 5 | Article 174 | 10
Haabeth et al. CD4+ T cell-mediated killing of tumors
20. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR,
et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by
CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
J Immunol (2005) 174:2591–601.
21. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al.
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-
ESO-1. N Engl J Med (2008) 358:2698–703. doi:10.1056/NEJMoa0800251
22. Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma
cells after transfection of MHC class II genes. J Immunol (1990) 144:
4068–71.
23. Ostrand-Rosenberg S, Roby CA, Clements VK. Abrogation of tumorigenicity
by MHC class II antigen expression requires the cytoplasmic domain of the
class II molecule. J Immunol (1991) 147:2419–22.
24. Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role
of tumor-specific Lyt-1+2– T cells in eradicating tumor cells in vivo. I. Lyt-
1+2– T cells do not necessarily require recruitment of host’s cytotoxic T cell
precursors for implementation of in vivo immunity. J Immunol (1984) 133:
1671–6.
25. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine
leukemia with cyclophosphamide and immune Lyt-1+,2– T cells. Tumor erad-
ication does not require participation of cytotoxic T cells. J Exp Med (1985)
161:1122–34. doi:10.1084/jem.161.5.1122
26. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-specific CD4+ T
cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A (1994)
91:5700–4. doi:10.1073/pnas.91.12.5700
27. Bogen B, Munthe L, Sollien A, Hofgaard P, Omholt H, Dagnaes F, et al. Naive
CD4+ T cells confer idiotype-specific tumor resistance in the absence of anti-
bodies. Eur J Immunol (1995) 25:3079–86. doi:10.1002/eji.1830251114
28. Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, Lantz O, et al.
CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood (2007)
109:5346–54. doi:10.1182/blood-2006-10-051318
29. Greenberg PD, Cheever MA, Fefer A. Eradication of disseminated murine
leukemia by chemoimmunotherapy with cyclophosphamide and adoptively
transferred immune syngeneic Lyt-1+2– lymphocytes. J Exp Med (1981)
154:952–63. doi:10.1084/jem.154.3.952
30. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H.
The central role of CD4(+) T cells in the antitumor immune response. J Exp
Med (1998) 188:2357–68. doi:10.1084/jem.188.12.2357
31. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD,
et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by
indirect effects of IFN-gamma. Proc Natl Acad Sci U S A (1999) 96:8633–8.
doi:10.1073/pnas.96.15.8633
32. Qin Z, Blankenstein T. CD4+ T cell – mediated tumor rejection involves inhi-
bition of angiogenesis that is dependent on IFN gamma receptor expression
by nonhematopoietic cells. Immunity (2000) 12:677–86. doi:10.1016/S1074-
7613(00)80218-6
33. Lundin KU, Hofgaard PO, Omholt H, Munthe LA, Corthay A, Bogen B.
Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lym-
phoma in the absence of anti-idiotypic antibodies. Blood (2003) 102:605.
doi:10.1182/blood-2002-11-3381
34. Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO, et al.
Primary antitumor immune response mediated by CD4+ T cells. Immunity
(2005) 22:371–83. doi:10.1016/j.immuni.2005.02.003
35. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-
specific Th17-polarized cells eradicate large established melanoma. Blood
(2008) 112:362–73. doi:10.1182/blood-2007-11-120998
36. Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B. Secretion of tumor-
specific antigen by myeloma cells is required for cancer immunosurveillance
by CD4+ T cells. Cancer Res (2009) 69:5901–7. doi:10.1158/0008-5472.CAN-
08-4816
37. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-
reactive CD4(+) T cells develop cytotoxic activity and eradicate large estab-
lished melanoma after transfer into lymphopenic hosts. J Exp Med (2010)
207:637–50. doi:10.1084/jem.20091918
38. Xie Y,Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EKM, et al. Naive tumor-
specific CD4+ T cells differentiated in vivo eradicate established melanoma.
(2010) 207:651–67. doi:10.1084/jem.20091921
39. Haabeth OA, Lorvik KB, Hammarstrom C, Donaldson IM, Haraldsen G, Bogen
B, et al. Inflammation driven by tumour-specific Th1 cells protects against B-
cell cancer. Nat Commun (2011) 2:240. doi:10.1038/ncomms1239
40. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis
of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Cancer Res (1999) 59:1071–9.
41. Klein L, Trautman L, Psarras S, Schnell S, Siermann A, Liblau R, et al. Visualiz-
ing the course of antigen-specific CD8 and CD4 T cell responses to a growing
tumor. Eur J Immunol (2003) 33:806–14. doi:10.1002/eji.200323800
42. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regula-
tory T cells following therapeutic cancer vaccines. Blood (2006) 107:628–36.
doi:10.1182/blood-2005-07-2737
43. Chamoto K, Wakita D, Narita Y, Zhang Y, Noguchi D, Ohnishi H, et al. An
essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions
in draining lymph node during complete eradication of class II-negative
tumor tissue by T-helper type 1 cell therapy. Cancer Res (2006) 66:1809–17.
doi:10.1158/0008-5472.CAN-05-2246
44. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, et al. Deplet-
ing tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin
Invest (2013) 123:2447–63. doi:10.1172/JCI64859
45. Bogen B, Malissen B, Haas W. Idiotope-specific T cell clones that recognize
syngeneic immunoglobulin fragments in the context of class II molecules. Eur
J Immunol (1986) 16:1373–8. doi:10.1002/eji.1830161110
46. Bogen B, Gleditsch L, Weiss S, Dembic Z. Weak positive selection of trans-
genic T cell receptor-bearing thymocytes: importance of major histocompati-
bility complex class II, T cell receptor and CD4 surface molecule densities. Eur
J Immunol (1992) 22:703–9. doi:10.1002/eji.1830220313
47. Lantz O, Grandjean I, Matzinger P, Di Santo JP. Gamma chain required for
naive CD4+ T cell survival but not for antigen proliferation. Nat Immunol
(2000) 1(1):54–8. doi:10.1038/76917
48. Scott B, Liblau R, Degermann S, Marconi LA, Ogata L, Caton AJ, et al. A
role for non-MHC genetic polymorphism in susceptibility to spontaneous
autoimmunity. Immunity (1994) 1(1):73–83. doi:10.1016/1074-7613(94)
90011-6
49. Kirberg J, Baron A, Jakob S, Rolink A, Karjalainen K, von Boehmer H.
Thymic selection of CD8+ single positive cells with a class II major histo-
compatibility complex-restricted receptor. J Exp Med (1994) 180(1):25–34.
doi:10.1084/jem.180.1.25
50. Murphy KM, Heimberger AB, Loh DY. Induction by antigen of intrathymic
apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science (1990)
250(4988):1720–23.
51. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in
transgenic mice constructed using cDNA-based alpha- and beta-chain genes
under the control of heterologous regulatory elements. Immunol Cell Biol
(1998) 76(1):34–40. doi:10.1046/j.1440-1711.1998.00709.x
52. Eisen HN, Simms ES, Potter M. Mouse myeloma proteins with antihapten
antibody activity. The protein produced by plasma cell tumor MOPC-315.
Biochemistry (1968) 7:4126–34. doi:10.1021/bi00851a048
53. Hannestad K, Kao MS, Eisen HN. Cell-bound myeloma proteins on the surface
of myeloma cells: potential targets for the immune system. Proc Natl Acad Sci
U S A (1972) 69(8):2295–9.
54. Xu Y, Setaluri V, Takechi Y, Houghton AN. Sorting and secretion of
a melanosome membrane protein, gp75/TRP1. J Invest Dermatol (1997)
109(6):788–95. doi:10.1111/1523-1747.ep12340971
55. Zenzes MT, Müller U, Aschmoneit I, Wolf U. Studies on H-Y antigen in differ-
ent cell fractions of the testis during pubescence: immature germ cells are H-Y
antigen negative. Hum Genet (1978) 45(3):297–303. doi:10.1007/BF00278727
56. Müller U. H-Y antigens. Hum Genet (1996) 97(6):701–4. doi:10.1007/
BF02346175
57. Copeland CS, Doms RW, Bolzau EM, Webster RG, Helenius A. Assembly of
influenza hemagglutinin trimers and its role in intracellular transport. J Cell
Biol (1986) 103(4):1179–91. doi:10.1083/jcb.103.4.1179
58. Meek RL, Walsh KA, Palmiter RD. The signal sequence of ovalbumin is located
near the NH2 terminus. J Biol Chem (1982) 257(20):12245–51.
59. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence
analysis of peptides bound to MHC class II molecules. Nature (1991)
353:622–7. doi:10.1038/353622a0
www.frontiersin.org April 2014 | Volume 5 | Article 174 | 11
Haabeth et al. CD4+ T cell-mediated killing of tumors
60. Benoist C, Mathis D. Regulation of major histocompatibility complex class-
II genes: X, Y and other letters of the alphabet. Annu Rev Immunol (1990)
8:681–715. doi:10.1146/annurev.immunol.8.1.681
61. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II tran-
scription. Annu Rev Immunol (1992) 10:13–49. doi:10.1146/annurev.iy.10.
040192.000305
62. Ting JP, Baldwin AS. Regulation of MHC gene expression. Curr Opin Immunol
(1993) 5:8–16. doi:10.1016/0952-7915(93)90074-3
63. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regula-
tion of MHC class II expression by interferon-gamma mediated by the trans-
activator gene CIITA. Science (1994) 265:106–9. doi:10.1126/science.8016643
64. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class
II genes: lessons from a disease. Annu Rev Immunol (1996) 14:301–31.
doi:10.1146/annurev.immunol.14.1.301
65. Dembic Z, Schenck K, Bogen B. Dendritic cells purified from myeloma are
primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc
Natl Acad Sci U S A (2000) 97:2697–702. doi:10.1073/pnas.050579897
66. Lundin KU, Screpanti V, Omholt H, Hofgaard PO, Yagita H, Grandien A, et al.
CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is domi-
nant in vitro but is redundant in vivo. Cancer Immunol Immunother (2004)
53:1135–45. doi:10.1007/s00262-004-0538-4
67. Wu GE, Hozumi N, Murialdo H. Secretion of a lambda 2 immunoglobulin
chain is prevented by a single amino acid substitution in its variable region.
Cell (1983) 33:77–83. doi:10.1016/0092-8674(83)90336-7
68. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor
cells secreting gamma-interferon is due to nonspecific host responses and is
unrelated to class I major histocompatibility complex expression. Cancer Res
(1991) 51(4):1185–9.
69. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into
the class I pathway of antigen processing and presentation. Cell (1988)
54(6):777–85.
70. Lauritzsen GF, Bogen B. The role of idiotype-specific, CD4+ T cells in tumor
resistance against major histocompatibility complex class II molecule nega-
tive plasmacytoma cells. Cell Immunol (1993) 148:177–88. doi:10.1006/cimm.
1993.1100
71. Tite JP, Janeway CA Jr. Cloned helper T cells can kill B lymphoma cells in the
presence of specific antigen: Ia restriction and cognate vs. noncognate interac-
tions in cytolysis. Eur J Immunol (1984) 14:878–86. doi:10.1002/eji.1830141004
72. Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, et al. In vivo dis-
ruption of tolerogenic cross-presentation mechanisms uncovers an effective
T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood
(2006) 107:2871–8. doi:10.1182/blood-2005-07-3014
73. Silacci P, Mottet A, Steimle V, Reith W, Mach B. Developmental extinction
of major histocompatibility complex class II gene expression in plasmocytes
is mediated by silencing of the transactivator gene CIITA. J Exp Med (1994)
180:1329–36. doi:10.1084/jem.180.4.1329
74. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of
MHC expression. Annu Rev Immunol (2001) 19:331–73. doi:10.1146/annurev.
immunol.19.1.331
75. Sanda T, Iida S, Kayukawa S, Ueda R. Induction of class II major histocom-
patibility complex expression in human multiple myeloma cells by retinoid.
Haematologica (2007) 92:115–20. doi:10.3324/haematol.10300
76. Yi Q, Dabadghao S, Osterborg A, Bergenbrant S, Holm G. Myeloma bone mar-
row plasma cells: evidence for their capacity as antigen-presenting cells. Blood
(1997) 90:1960–7.
77. Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT, et al. MHC class II
transactivator (CIITA) expression is upregulated in multiple myeloma cells by
IFN-gamma. Mol Immunol (2007) 44:2923–32. doi:10.1016/j.molimm.2007.
01.009
78. Bothwell AL, Paskind M, Reth M, Imanishi-Kari T, Rajewsky K, Baltimore
D. Somatic variants of murine immunoglobulin lambda light chains. Nature
(1982) 298:380–2. doi:10.1038/298380a0
79. Bogen B, Lambris JD. Minimum length of an idiotypic peptide and a model
for its binding to a major histocompatibility complex class II molecule. EMBO
J (1989) 8:1947–52.
80. Weiss S, Bogen B. B-lymphoma cells process and present their endogenous
immunoglobulin to major histocompatibility complex-restricted T cells. Proc
Natl Acad Sci U S A (1989) 86:282–6. doi:10.1073/pnas.86.1.282
81. Jorgensen T, Hannestad K. Helper T cell recognition of the variable domains
of a mouse myeloma protein (315). Effect of the major histocompatibil-
ity complex and domain conformation. J Exp Med (1982) 155:1587–96.
doi:10.1084/jem.155.6.1587
82. Foy TM, Lynch RG, Waldschmidt TJ. Ontogeny and distribution of the murine
B cell Fc gamma RII. J Immunol (1992) 149:1516–23.
83. Winberry L, Marks A, Baumal R. Immunoglobulin production and secretion
by variant clones of the MOPC 315 mouse myeloma cell line. J Immunol (1980)
124:1174–82.
84. Corthay A, Lorvik KB, Bogen B. Is secretion of tumour-specific antigen impor-
tant for cancer eradication by CD4(+) T cells? – Implications for cancer
immunotherapy by adoptive T cell transfer. Scand J Immunol (2011) 73:527–30.
doi:10.1111/j.1365-3083.2011.02558.x
85. Lorvik KB, Haabeth OA, Clancy T, Bogen B, Corthay A. Molecular profiling of
tumor-specific T1 cells activated in vivo. Oncoimmunology (2013) 2:e24383.
doi:10.4161/onci.24383
86. Lorvik KB, Bogen B, Corthay A. Fingolimod blocks immunosurveillance of
myeloma and B-cell lymphoma resulting in cancer development in mice. Blood
(2012) 119:2176–7. doi:10.1182/blood-2011-10-388892
87. Haabeth OA, Bogen B, Corthay A. A model for cancer-suppressive inflamma-
tion. Oncoimmunology (2012) 1:1146–55. doi:10.4161/onci.21542
88. Bogen B, Schenck K, Munthe LA, Dembic Z. Deletion of idiotype (Id)-
specific T cells in multiple myeloma. Acta Oncol (2000) 39:783–8. doi:10.1080/
028418600750063505
89. Staveley-O’Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein
S, et al. Induction of antigen-specific T cell anergy: an early event in the
course of tumor progression. Proc Natl Acad Sci U S A (1998) 95:1178–83.
doi:10.1073/pnas.95.3.1178
90. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contex-
ture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012)
12:298–306. doi:10.1038/nrc3245
91. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of
changing circumstances. Nat Immunol (2010) 11:674–80. doi:10.1038/ni.1899
92. O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plastic-
ity of helper CD4+ T cells. Science (2010) 327:1098–102. doi:10.1126/science.
1178334
93. Bogen B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of
CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted
by a plasmacytoma. Eur J Immunol (1996) 26:2671–9. doi:10.1002/eji.
1830261119
94. Lauritzsen GF, Hofgaard PO, Schenck K, Bogen B. Clonal deletion of thy-
mocytes as a tumor escape mechanism. Int J Cancer (1998) 78:216–22.
doi:10.1002/(SICI)1097-0215(19981005)78:2<216::AID-IJC16>3.0.
95. Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, et al. Restor-
ing immune function of tumor-specific CD4+ T cells during recurrence
of melanoma. J Immunol (2013) 190:4899–909. doi:10.4049/jimmunol.
1300271
96. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O’carroll
K, et al. Cross-presentation of tumor antigens by bone marrow-derived
antigen-presenting cells is the dominant mechanism in the induction of T-
cell tolerance during B-cell lymphoma progression. Blood (2001) 98:1070–7.
doi:10.1182/blood.V98.4.1070
97. Morse HC III, Kearney JF, Isaacson PG, Carroll M, Fredrickson TN, Jaffe ES.
Cells of the marginal zone – origins, function and neoplasia. Leuk Res (2001)
25:169–78. doi:10.1016/S0145-2126(00)00107-7
98. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer
(2005) 5:251–62. doi:10.1038/nrc1589
99. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular
profiling of diffuse large B-cell lymphoma identifies robust subtypes including
one characterized by host inflammatory response. Blood (2005) 105:1851–61.
doi:10.1182/blood-2004-07-2947
100. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+ T-cell
immune response to large B-cell non-Hodgkin’s lymphoma predicts patient
outcome. J Clin Oncol (2001) 19:720–6.
101. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al.
Prediction of survival in follicular lymphoma based on molecular features
of tumor-infiltrating immune cells. N Engl J Med (2004) 351:2159–69.
doi:10.1056/NEJMoa041869
Frontiers in Immunology | Tumor Immunity April 2014 | Volume 5 | Article 174 | 12
Haabeth et al. CD4+ T cell-mediated killing of tumors
102. Zangani MM, Froyland M, Qiu GY, Meza-Zepeda LA, Kutok JL, Thomp-
son KM, et al. Lymphomas can develop from B cells chronically helped by
idiotype-specific T cells. J Exp Med (2007) 204:1181–91. doi:10.1084/jem.
20061220
103. Os A, Burgler S, Ribes AP, Funderud A, Wang D, Thompson KM, et al. Chronic
lymphocytic leukemia cells are activated and proliferate in response to specific
T helper cells. Cell Rep (2013) 4:566–77. doi:10.1016/j.celrep.2013.07.011
104. Ostad M, Andersson M, Gruber A, Sundblad A. Expansion of immunoglobu-
lin autoreactive T-helper cells in multiple myeloma. Blood (2008) 111:2725–32.
doi:10.1182/blood-2006-11-056242
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 17 February 2014; paper pending published: 07 March 2014; accepted: 02
April 2014; published online: 15 April 2014.
Citation: Haabeth OAW, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hof-
gaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A and Bogen B (2014) How
do CD4+ T cells detect and eliminate tumor cells that either lack or express MHC class
II molecules? Front. Immunol. 5:174. doi: 10.3389/fimmu.2014.00174
This article was submitted to Tumor Immunity, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Haabeth, Tveita, Fauskanger, Schjesvold, Lorvik, Hofgaard,
Omholt , Munthe, Dembic, Corthay and Bogen. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org April 2014 | Volume 5 | Article 174 | 13
